PMID- 21083700
OWN - NLM
STAT- MEDLINE
DCOM- 20110504
LR  - 20221207
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 38
IP  - 1
DP  - 2011 Jan
TI  - Relationship between serum osteocalcin and glycaemic variability in Type 2 
      diabetes.
PG  - 50-4
LID - 10.1111/j.1440-1681.2010.05463.x [doi]
AB  - 1. Recent reports have described the role of osteocalcin in glucose metabolism 
      and glycaemic variability has been proven to be associated with an increased risk 
      of diabetes complications. However, the relationship between osteocalcin and 
      glycaemic variability remains unclear. The aim of the present study was to 
      examine the relationship between serum osteocalcin and glycaemic variability, as 
      determined by a continuous glucose monitoring (CGM) system in patients with Type 
      2 diabetes mellitus (T2DM). 2. Fifty-nine T2DM patients with glycosylated 
      haemoglobin (HbA1c) levels between 7.0% and 10.9% were recruited to the present 
      study. Biochemical information and CGM parameters were collected at baseline and 
      after 8 weeks of antihyperglycaemic therapy (either sulphonylurea, sulphonylurea 
      + an alpha-glucosidase inhibitor or insulin + metformin combination therapy). 3. 
      Compared with baseline, serum osteocalcin increased significantly (P = 0.014), 
      whereas parameters related to glucose variability, including the mean amplitude 
      of glycaemic excursions (MAGE) and the standard deviation of blood glucose 
      values, decreased significantly (P < 0.001) after the 8 week treatment period. At 
      baseline, there was a positive correlation between serum osteocalcin levels and 
      fasting C-peptide levels (P = 0.004) and homeostatic model assessment of beta-cell 
      function (P = 0.048), but a negative correlation between serum osteocalcin levels 
      and fasting plasma glucose (P = 0.023), HbA1c (P = 0.020), glycated albumin (P = 
      0.019) and 24 h mean blood glucose (P < 0.001). Multiple stepwise regression 
      analysis indicated that baseline osteocalcin was the single parameter that best 
      predicted the change in MAGE (beta = -0.122; P = 0.039). 4. In conclusion, serum 
      osteocalcin concentrations increased with improved glucose control. High initial 
      osteocalcin levels were associated with subsequent improvements in glucose 
      variability during glucose-lowering treatment.
CI  - (c) 2010 The Authors. Clinical and Experimental Pharmacology and Physiology (c) 2010 
      Blackwell Publishing Asia Pty Ltd.
FAU - Bao, Yu-Qian
AU  - Bao YQ
AD  - Department of Endocrinology and Metabolism, Shanghai Clinical Center for 
      Diabetes, Shanghai, China.
FAU - Zhou, Mi
AU  - Zhou M
FAU - Zhou, Jian
AU  - Zhou J
FAU - Lu, Wei
AU  - Lu W
FAU - Gao, Yun-Chao
AU  - Gao YC
FAU - Pan, Xiao-Ping
AU  - Pan XP
FAU - Tang, Jun-Ling
AU  - Tang JL
FAU - Lu, Hui-Juan
AU  - Lu HJ
FAU - Jia, Wei-Ping
AU  - Jia WP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Blood Glucose)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 104982-03-8 (Osteocalcin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/analysis/drug effects/*metabolism
MH  - Blood Glucose Self-Monitoring
MH  - Diabetes Mellitus, Type 2/*blood/metabolism
MH  - Enzyme Inhibitors/administration & dosage/adverse effects
MH  - Female
MH  - Glycated Hemoglobin/analysis/metabolism
MH  - Glycoside Hydrolase Inhibitors
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - Individuality
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - Metformin/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Observer Variation
MH  - Osteocalcin/analysis/*blood
MH  - Sulfonylurea Compounds/administration & dosage/adverse effects
EDAT- 2010/11/19 06:00
MHDA- 2011/05/05 06:00
CRDT- 2010/11/19 06:00
PHST- 2010/11/19 06:00 [entrez]
PHST- 2010/11/19 06:00 [pubmed]
PHST- 2011/05/05 06:00 [medline]
AID - 10.1111/j.1440-1681.2010.05463.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2011 Jan;38(1):50-4. doi: 
      10.1111/j.1440-1681.2010.05463.x.